Prista Leão Beatriz, Abreu Isabel, Cláudia Carvalho Ana, Sarmento António, Santos Lurdes
Infectious Diseases Department, Centro Hospitalar Universitário de São João, Oporto, Portugal.
Both authors contributed equally to this manuscript as joint first authors.
Curr Med Mycol. 2020 Dec;6(4):47-53. doi: 10.18502/cmm.6.4.5437.
Prevalence of mucormycosis is growing with the increase of the population at risk. Current recommendations for its management are mostly based on retrospective studies. 3 study aimed to present the cumulative experience of an Infectious Diseases Department from a Portuguese hospital in the management of mucormycosis and discuss the potential gaps in the diagnostic and therapeutic approaches of this infection.
For the purposes of the study, the electronic hospital database was searched for adult patients with mucormycosis from 1996 to 2019 based on the definition provided by the Consensus Definitions of Invasive Fungal Disease. Demographic, clinical, treatment, and outcome data were collected and compared to what had been described in the related literature.
In total, 15 cases of mucormycosis were found, including 11 cases with sinus involvement (10 with central nervous system involvement), two pulmonary, and two gastrointestinal infections. Diabetes mellitus (n=7) and corticosteroid therapy (n=7) were frequent risk factors. Median duration of symptoms before the suspicion of diagnosis was 26 days (3-158). The diagnosis was confirmed in 12 patients mostly by histopathology (n=9); the culture was positive only once. Systemic antifungals and surgical debridement were the backbones of treatment; however, side effects, the need for therapeutic drug monitoring, and the anatomical location of lesions added complexity to management. Overall, seven patients died, two of them before the consideration of clinical suspicion.
More medications are becoming available for the treatment of mucormycosis. Nevertheless, we believe that its prognosis will only significantly change through the increase of awareness and reduction of the time to diagnosis. An effective multidisciplinary approach among surgeons, infectious diseases specialists, radiologists, microbiologists, and anatomopathologists is critical to the achievement of this goal.
随着高危人群数量的增加,毛霉病的患病率正在上升。目前针对其治疗的建议大多基于回顾性研究。本研究旨在介绍一家葡萄牙医院感染科在毛霉病治疗方面的累积经验,并探讨这种感染在诊断和治疗方法上可能存在的差距。
为进行本研究,根据侵袭性真菌病共识定义所提供的定义,在医院电子数据库中搜索1996年至2019年期间的成年毛霉病患者。收集人口统计学、临床、治疗及结局数据,并与相关文献中所描述的情况进行比较。
共发现15例毛霉病病例,包括11例鼻窦受累(其中10例伴有中枢神经系统受累)、2例肺部感染和2例胃肠道感染。糖尿病(n = 7)和皮质类固醇治疗(n = 7)是常见的危险因素。怀疑诊断前症状的中位持续时间为26天(3 - 158天)。12例患者主要通过组织病理学确诊(n = 9);培养仅一次呈阳性。全身抗真菌药物和手术清创是治疗的主要手段;然而,副作用、治疗药物监测的必要性以及病变的解剖位置增加了治疗的复杂性。总体而言,7例患者死亡,其中2例在临床怀疑之前死亡。
越来越多的药物可用于治疗毛霉病。尽管如此,我们认为只有通过提高认识和缩短诊断时间,其预后才会显著改善。外科医生、感染病专家、放射科医生、微生物学家和解剖病理学家之间有效的多学科方法对于实现这一目标至关重要。